Heritage Bio Labs
Research Library
Explore 411 articles about peptides, research compounds and related topics, with links to the original studies.
Find articles
Matching articles
Showing 109–120 of 124 articles · Check methods and identity
- Check methods and identity
What bioequivalence means in a comparison of tesamorelin formulations
Tesamorelin is a chemically modified 44-residue analogue of growth hormone–releasing hormone. A report published in January 2026 compared how the newer Egrifta WR formulation and the original Egrifta formulation appeared in the blood of healthy adults.
Tesamorelin2 sources (2026)
- Check methods and identity
What a liver-fat trial measured beyond abdominal fat
Tesamorelin is a chemically modified, 44-residue analogue of growth hormone–releasing hormone that stimulates the pituitary. An older trial asked whether the drug affected fat stored in the liver in adults with HIV and fatty liver disease.
Tesamorelin2 sources (2019, 2026)
- Check methods and identity
What a 2026 Thymalfasin Sepsis Registry Entry Plans to Measure
Thymosin alpha-1 is an immune-related peptide, and thymalfasin is its drug form. An October 2026 trial registration describes a study in adults with sepsis and signs of reduced immune function. It records a research plan and does not report a result.
Thymosin Alpha-11 source (2026)
- Check methods and identity
Why Thymosin Alpha 1 Needs Its Own Identity and Regulatory Evidence
Thymosin alpha-1 is a 28-amino-acid peptide studied in immune biology. It is distinct from thymosin beta-4 and from materials described as fragments of beta-4. An article about one should not inherit the clinical or regulatory evidence for the other.
Thymosin Alpha-13 sources (2024, 2026)
- Check methods and identity
What the Japanese tirzepatide trial measured around the abdomen
Tirzepatide is a modified peptide that activates GIP and GLP-1 receptors. The “GLP-2” in this catalog label is an identifier and does not describe tirzepatide’s receptor targets.
TIRZ GLP-21 source (2026)
- Check methods and identity
How sleep and weight measurements related to blood pressure
Tirzepatide acts at GIP and GLP-1 receptors, regardless of the “GLP-2” wording used in the catalog. A 2026 analysis of the SURMOUNT-OSA trials examined how changes in sleep apnea measurements and weight were related to changes in cardiovascular risk markers.
TIRZ GLP-22 sources (2024, 2026)
- Check methods and identity
Why two compounds given together and a single formulation are separate questions
Tirzepatide is a GIP and GLP-1 receptor agonist peptide. IGF-1 LR3 is a modified version of the growth-factor protein IGF-1. Studies registered for tirzepatide with a different molecule illustrate why the preparation is part of what researchers have to define.
TIRZ / IGF-1 LR33 sources (2023–2026)
- Check methods and identity
How an assay separates intact IGF-1 LR3 from its breakdown products
Tirzepatide is a peptide that activates GIP and GLP-1 receptors, while IGF-1 LR3 is an engineered growth-factor protein. Older research developed a way to distinguish the intact growth-factor analog from related molecules and some of its breakdown products.
TIRZ / IGF-1 LR32 sources (2021, 2026)
- Check methods and identity
Why studies measure food intake separately from body weight
Tirzepatide activates GIP and GLP-1 receptors. IGF-1 LR3 is an engineered, extended version of insulin-like growth factor 1. Older direct experiments on each component help explain why a study of the pair would need to measure food intake separately from weight and tissue outcomes.
TIRZ / IGF-1 LR32 sources (1997, 2025)
- Check methods and identity
What the COURAGE MRI substudy measured in the thigh
Trevogrumab is an investigational monoclonal antibody, a large protein engineered to block myostatin, also called GDF8. In 2026, the COURAGE trial sponsor reported an MRI substudy that asked whether adding this antibody to semaglutide changed thigh muscle volume.
Trevogrumab3 sources (2024–2026)
- Check methods and identity
How animal studies tested muscle and fat during weight change
Trevogrumab is an investigational monoclonal antibody that blocks myostatin. An older study in male mice and nonhuman primates examined what happened to lean tissue and fat when investigators blocked myostatin and activin A during treatment with a GLP-1 receptor agonist.
Trevogrumab2 sources (2024–2026)
- Check methods and identity
What an older sarcopenia trial measured with a body scan
Trevogrumab, also called REGN1033 in earlier studies, is a larger investigational antibody that blocks myostatin. An older randomized study in people with sarcopenia tested whether the antibody changed lean body mass over 12 weeks.
Trevogrumab3 sources (2013–2026)
Browse by product
- A4 Amyloid Beta6 articles
- ACE-0316 articles
- ACE-0836 articles
- Adipotide6 articles
- AICAR6 articles
- AOD-96046 articles
- ARA-2906 articles
- BPC-1576 articles
- BPC-157 / TB-5006 articles
- Cagrilintide7 articles
- CJC-1295 (No DAC) / GHRP-26 articles
- CJC-1295 (No DAC) / GHRP-66 articles
- CJC-1295 (No DAC) / Ipamorelin6 articles
- CJC-1295 No DAC6 articles
- CJC-1295 With DAC6 articles
- DSIP6 articles
- Epitalon6 articles
- Follistatin 3156 articles
- Follistatin 3446 articles
- Fragment 176-1916 articles
- GHK-Cu6 articles
- GHRP-26 articles
- GHRP-66 articles
- GLOW 2 Blend6 articles
- GLOW Blend6 articles
- GLP-1 SEMA6 articles
- GLP-2 TIRZ6 articles
- Glutathione6 articles
- HCG6 articles
- Hexarelin6 articles
- Human Relaxin-26 articles
- IGF-1 DES 1,36 articles
- IGF-1 Human6 articles
- IGF-2 LR36 articles
- IGF-DES 1,36 articles
- IGF-LR36 articles
- Ipamorelin6 articles
- Kisspeptin-106 articles
- KLOW Blend6 articles
- KPV6 articles
- Lipopeptide6 articles
- Liraglutide6 articles
- Melanotan II5 articles
- MGF6 articles
- MOTS-C6 articles
- MSC Exosomes6 articles
- Myostatin6 articles
- Myostatin HMP (GDF8)6 articles
- Oxytocin7 articles
- PEG-MGF6 articles
- Pinealon6 articles
- PT-1416 articles
- RETA / IGF-1 LR36 articles
- RETA GLP-36 articles
- Selank6 articles
- SEMA / IGF-1 LR36 articles
- Semax6 articles
- Sermorelin6 articles
- SLU-PP-3326 articles
- SNAP-86 articles
- Survodutide7 articles
- TB-5006 articles
- Tesamorelin6 articles
- Thymosin Alpha-16 articles
- TIRZ / IGF-1 LR36 articles
- TIRZ GLP-26 articles
- Trevogrumab6 articles
- Triptorelin GnRH6 articles
